ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
ArriVent BioPharma Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
ArriVent BioPharma Reports Third Quarter 2024 Financial Results
ArriVent BioPharma: Bringing A Novel Cancer Drug From China [Seeking Alpha]
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its price target raised by analysts at Citigroup Inc. from $30.00 to $36.00. They now have a "buy" rating on the stock.